Oral hypoglycemic agents in the current treatment of Diabetes Mellitus type 2: Inhibidores de la dipeptidil peptidasa tipo-4

Descripción del Articulo

The concept of incretin effect and its application in the development of drugs that help to control the glycemia in patients with diabetes mellitus type 2 (DM2) is described. Once it was found that this effect was altered in people with diabetes and discovered that this enzyme metabolizes these inte...

Descripción completa

Detalles Bibliográficos
Autor: Arbañil- Huamán, Hugo César
Formato: artículo
Fecha de Publicación:2020
Institución:Fundación Instituto Hipólito Unanue
Repositorio:Diagnóstico
Lenguaje:español
OAI Identifier:oai:revistadiagnostico.fihu.org.pe:article/218
Enlace del recurso:https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/218
Nivel de acceso:acceso abierto
Materia:Diabetes Mellitus tipo 2
Tratamiento
inhibidores de la DPP-4
Diabetes Mellitus type 2
treatment
DPP-4-inhibitors
id REVFIHU_f4ac4dcf97c407305714a68070b51730
oai_identifier_str oai:revistadiagnostico.fihu.org.pe:article/218
network_acronym_str REVFIHU
network_name_str Diagnóstico
repository_id_str
spelling Oral hypoglycemic agents in the current treatment of Diabetes Mellitus type 2: Inhibidores de la dipeptidil peptidasa tipo-4Hipoglicemiantes orales en el tratamiento actual de la Diabtetes Mellitus tipo 2: Inhibidores de la dipeptidil peptidasa tipo-4Arbañil- Huamán, Hugo CésarDiabetes Mellitus tipo 2Tratamientoinhibidores de la DPP-4Diabetes Mellitus type 2treatmentDPP-4-inhibitorsThe concept of incretin effect and its application in the development of drugs that help to control the glycemia in patients with diabetes mellitus type 2 (DM2) is described. Once it was found that this effect was altered in people with diabetes and discovered that this enzyme metabolizes these intestinal hormones, it begin the development of increasingly more specific inhibitors of the enzyme dipeptidil peptidase type-4 /DPP-4). Thereafter the results of cardiovascular safety studies are presented and how these drugs have been positioned in the management guidelines of DM2.Se describe la evolución del concepto del efecto incretina y su aplicación al desarrollo de medicamentos que ayudan al control de la glicemia en personas con diabetes mellitus tipo 2 (DM2). Al encontrarse que este efecto estaba alterado en personas con DM2 y descubrir la enzima que metaboliza a estas hormonas intestinales, se empezó el desarrollo de inhibidores cada vez más específicos de la enzima dipeptidil peptidasa-4 (DPP-4). Posteriormente, se presenta los resultados de los estudios de seguridad cardiovascular y sobre el posicionamiento de estos medicamentos en las guías de manejo de la DM2.Fundación Instituto Hipólito Unanue2020-11-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/21810.33734/diagnostico.v59i2.218Diagnóstico; Vol. 59 No. 2 (2020); 61-64Diagnostico; Vol. 59 Núm. 2 (2020); 61-641018-28882709-795110.33734/diagnostico.v59i2reponame:Diagnósticoinstname:Fundación Instituto Hipólito Unanueinstacron:FIHUspahttps://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/218/222Derechos de autor 2020 Hugo César Arbañil- Huamáninfo:eu-repo/semantics/openAccessoai:revistadiagnostico.fihu.org.pe:article/2182021-06-04T17:58:36Z
dc.title.none.fl_str_mv Oral hypoglycemic agents in the current treatment of Diabetes Mellitus type 2: Inhibidores de la dipeptidil peptidasa tipo-4
Hipoglicemiantes orales en el tratamiento actual de la Diabtetes Mellitus tipo 2: Inhibidores de la dipeptidil peptidasa tipo-4
title Oral hypoglycemic agents in the current treatment of Diabetes Mellitus type 2: Inhibidores de la dipeptidil peptidasa tipo-4
spellingShingle Oral hypoglycemic agents in the current treatment of Diabetes Mellitus type 2: Inhibidores de la dipeptidil peptidasa tipo-4
Arbañil- Huamán, Hugo César
Diabetes Mellitus tipo 2
Tratamiento
inhibidores de la DPP-4
Diabetes Mellitus type 2
treatment
DPP-4-inhibitors
title_short Oral hypoglycemic agents in the current treatment of Diabetes Mellitus type 2: Inhibidores de la dipeptidil peptidasa tipo-4
title_full Oral hypoglycemic agents in the current treatment of Diabetes Mellitus type 2: Inhibidores de la dipeptidil peptidasa tipo-4
title_fullStr Oral hypoglycemic agents in the current treatment of Diabetes Mellitus type 2: Inhibidores de la dipeptidil peptidasa tipo-4
title_full_unstemmed Oral hypoglycemic agents in the current treatment of Diabetes Mellitus type 2: Inhibidores de la dipeptidil peptidasa tipo-4
title_sort Oral hypoglycemic agents in the current treatment of Diabetes Mellitus type 2: Inhibidores de la dipeptidil peptidasa tipo-4
dc.creator.none.fl_str_mv Arbañil- Huamán, Hugo César
author Arbañil- Huamán, Hugo César
author_facet Arbañil- Huamán, Hugo César
author_role author
dc.subject.none.fl_str_mv Diabetes Mellitus tipo 2
Tratamiento
inhibidores de la DPP-4
Diabetes Mellitus type 2
treatment
DPP-4-inhibitors
topic Diabetes Mellitus tipo 2
Tratamiento
inhibidores de la DPP-4
Diabetes Mellitus type 2
treatment
DPP-4-inhibitors
description The concept of incretin effect and its application in the development of drugs that help to control the glycemia in patients with diabetes mellitus type 2 (DM2) is described. Once it was found that this effect was altered in people with diabetes and discovered that this enzyme metabolizes these intestinal hormones, it begin the development of increasingly more specific inhibitors of the enzyme dipeptidil peptidase type-4 /DPP-4). Thereafter the results of cardiovascular safety studies are presented and how these drugs have been positioned in the management guidelines of DM2.
publishDate 2020
dc.date.none.fl_str_mv 2020-11-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/218
10.33734/diagnostico.v59i2.218
url https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/218
identifier_str_mv 10.33734/diagnostico.v59i2.218
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/218/222
dc.rights.none.fl_str_mv Derechos de autor 2020 Hugo César Arbañil- Huamán
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Derechos de autor 2020 Hugo César Arbañil- Huamán
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Fundación Instituto Hipólito Unanue
publisher.none.fl_str_mv Fundación Instituto Hipólito Unanue
dc.source.none.fl_str_mv Diagnóstico; Vol. 59 No. 2 (2020); 61-64
Diagnostico; Vol. 59 Núm. 2 (2020); 61-64
1018-2888
2709-7951
10.33734/diagnostico.v59i2
reponame:Diagnóstico
instname:Fundación Instituto Hipólito Unanue
instacron:FIHU
instname_str Fundación Instituto Hipólito Unanue
instacron_str FIHU
institution FIHU
reponame_str Diagnóstico
collection Diagnóstico
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1847792815892856832
score 13.058573
Oral hypoglycemic agents in the current treatment of Diabetes Mellitus type 2: Inhibidores de la dipeptidil peptidasa tipo-4
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).

Ejemplares Similares